BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 23605387)

  • 1. Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?
    Gerlach M; Grünblatt E; Lange KW
    Atten Defic Hyperact Disord; 2013 Jun; 5(2):71-81. PubMed ID: 23605387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.
    Fone KC; Nutt DJ
    Curr Opin Pharmacol; 2005 Feb; 5(1):87-93. PubMed ID: 15661631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.
    Heal DJ; Cheetham SC; Smith SL
    Neuropharmacology; 2009 Dec; 57(7-8):608-18. PubMed ID: 19761781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
    Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.
    Kollins SH
    J Clin Psychiatry; 2003; 64 Suppl 11():14-8. PubMed ID: 14529325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO; Liliemark J; Klintberg K; von Knorring AL
    Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.
    Faraone SV
    Neurosci Biobehav Rev; 2018 Apr; 87():255-270. PubMed ID: 29428394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children.
    Kociancic T; Reed MD; Findling RL
    Expert Opin Drug Saf; 2004 Mar; 3(2):93-100. PubMed ID: 15006715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
    Merkel RL; Kuchibhatla A
    Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Apropos the National Board and Welfare's report on ADDH: some views on the treatment with central nervous system stimulants].
    Zetterström R
    Lakartidningen; 2002 Aug; 99(35):3435-6. PubMed ID: 12362770
    [No Abstract]   [Full Text] [Related]  

  • 16. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines.
    Kollins SH
    J Atten Disord; 2008 Sep; 12(2):115-25. PubMed ID: 18192623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
    Işeri E; Kiliç BG; Senol S; Karabacak NI
    Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of stimulants on height and weight: a review of the literature.
    Faraone SV; Biederman J; Morley CP; Spencer TJ
    J Am Acad Child Adolesc Psychiatry; 2008 Sep; 47(9):994-1009. PubMed ID: 18580502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.